Research Journal of Pharmacology and Pharmacodynamics

Open Access Open Access  Restricted Access Subscription Access
Open Access Open Access Open Access  Restricted Access Restricted Access Subscription Access

A New Profile of Therapeutic Potential and Toxicities of Antineoplastic Drugs


Affiliations
1 Institute of Pharmacy, RITEE, Chhatauna, Mandir Hasaud, Raipur, Chhattisgarh, India
2 Samskruti College of Pharmacy, Kondapur, Ghatkesar, RR Dist., Hyderabad, Andhra Pradesh, India
3 Anwarul Uloom College of Pharmacy, New Mallepally, Hyderabad, Andhra Pradesh, India
     

   Subscribe/Renew Journal


Anticancer or antineoplastic drugs are used to treat malignancies. Drug therapy may be used alone or in combination with other treatments such as surgery or radiation therapy. The available anticancer drugs have distinct mechanisms of action which may vary in their effects on different types of normal and cancer cells. A single cure for cancer has proved elusive since there is not a single type of cancer but as many as 100 different types of cancer. In addition, there are very few demonstrable biochemical differences between cancerous cells and normal cells. For this reason the effectiveness of many anticancer drugs is limited by their toxicity to normal rapidly growing cells. A final problem is that cancerous cells which are initially suppressed by a specific drug may develop a resistance to that drug. For this reason cancer chemotherapy may consist of using several drugs in combination for varying lengths of time.

Keywords

Antineoplastic, Malignancies, Therapy, Toxicity.
Subscription Login to verify subscription
User
Notifications
Font Size


  • The Valuable Contribution of al-Razi (Rhazes) to the History of Pharmacy. FSTC. 2007.

  • Hirsch J. An anniversary for cancer chemotherapy. JAMA. 2006; 296 (12): 1518-1520.

  • Goodman LS, Wintrobe MM, Dameshek W, Goodman MJ, Gilman A, McLennan MT. Nitrogen mustard therapy. JAMA. 1946; 132: 26-32.

  • Goodman LS, Wintrobe MM, Dameshek W, Goodman MJ, Gilman A, McLennan MT. Nitrogen mustard therapy. JAMA. 1984; 251 (17): 2255-2261.

  • Joensuu H. Systemic chemotherapy for cancer: from weapon to treatment. Lancet Oncol. 2008; 9 (3): 304.

  • Somkumar, A. P., Studies on anticancer effects of Ocimum sanctum and Withania somnifera on experimentally induced cancer in mice. Ph D thesis, J. N. K. V. V., Jabalpur, 2003.

  • Pandey, Govind and Madhuri, S., Medicinal plants: better remedy for neoplasm. Indian Drugs. 2006; 43: 869-874.

  • Nielsen OH, Vainer B, Rask-Madsen J. Review article: the treatment of inflammatory bowel disease with 6-mercaptopurine or azathioprine. Aliment. Pharmacol. Ther. 2001 15 (11): 1699-1708.

  • http://www3.interscience.wiley.com/resolve/openurl?genre=articleandsid=nlm:pubmedandissn=0269-2813andd ate=2001andvolume=15andissue=11andspage=1699.

  • Sahasranaman S, Howard D, Roy S. Clinical pharmacology and pharmacogenetics of thiopurines. Eur. J. Clin. Pharmacol. 2008; 64 (8): 753-767.

  • http://www.cancer.gov/templates/db_alpha.aspx?CdrID=44916

  • Arcamone G, Cassinelli G, Fantini A, Grein P. Adriamycin, 14-hydroxydaimomycin, a new antitumor antibiotic from S. Peucetius var. caesius. Biotechnology and Bioengineering. 1969; 11: 1101-1110.

  • Weiss RB. The anthracyclines: will we ever find a better doxorubicin. Semin. Oncol. 1992; 19 (6): 670-686.

  • Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol. Rev. 2004; 56 (2): 185-229.

  • Peng X, Chen B, Lim CC, Sawyer DB. The cardiotoxicology of anthracycline chemotherapeutics: translating molecular mechanism into preventative medicine. mol. interv. 2005; 5(3): 163-171.

  • Weiss RB. The anthracyclines: will we ever find a better doxorubicin. Semin. Oncol. 1992; 19 (6): 670-686.

  • Vandenberg T, Trudeau M, Coakley N. Regional Models of Care for Systemic Treatment: Standards for the Organization and Delivery of Systemic Treatment Cancer Care Ontario. 2007.

  • Henderson M. Lung cancer drug may fight breast tumor in women. 2006. Times online http://www.timesonline.co.uk/tol/news/uk/article711744.ece.

  • Cetuximab Beneficial in Head and Neck Cancer - National Cancer Institute. J. Clin. Oncol. 2010.

  • http://finance.yahoo.com/news/Nimotuzumab-Demonstratesprnews-15396981.html?.v=8

  • Pruefer FG, Lizarraga F, Maldonado V, Melendez-Zajgla J. Participation of Omi Htra2 serine-protease activity in the apoptosis induced by cisplatin on SW480 colon cancer cells. J Chemother. 2008; 20 (3): 348-354.

  • Stephen Trzaska. Cisplatin. CandEN News 83 (25). 2005. http://pubs.acs.org/cen/coverstory/83/8325/8325cisplatin.html.

  • Aurer I, Mitrovic Z, Kovacevic-Metelko J. Treatment of hairy cell leukemia with cladribine. Lijec Vjesn. 2007; 129 (3-4): 80-83.

  • Robak T, Jamroziak K, Gora-Tybor J. Cladribine in a weekly versus daily schedule for untreated active hairy cell leukemia: final report from the Polish Adult Leukemia Group (PALG) of a prospective, randomized, multicenter trial. Blood. 2007; 109 (9): 3672-3675.

  • Van Den Neste E, Delannoy A, Vandercam B. Infectious complications after 2-chlorodeoxyadenosine therapy. Eur. J. Haematol. 1996; 56 (4): 235-240.

  • Saven A, Burian C, Adusumalli J, Koziol JA. Filgrastim for cladribine-induced neutropenic fever in patients with hairy cell leukemia. Blood. 1999; 93 (8): 2471-2477.

  • Nelson MC, Hogan DK. The role of cladribine in the treatment of lymphoid malignancies. Oncol Nurs Forum. 1995; 22 (9): 1395-1400.

  • Lauria F, Benfenati D, Raspadori D. Retreatment with 2-CdA of progressed HCL patients. Leuk. Lymphoma 14 Suppl. 1994; 1: 143-145.

  • Lauria F, Benfenati D, Raspadori D, Rondelli D, Zinzani PL, Tura S. High complete remission rate in hairy cell leukemia treated with 2-chlorodeoxyadenosine. Leuk. Lymphoma. 1993; 11 (5-6): 399-404.

  • Lauria F, Benfenati D, Raspadori D. Retreatment with 2-CdA of progressed HCL patients. Leuk. Lymphoma 14 Suppl. 1994; 1: 143-145.

  • Saven A, Burian C, Adusumalli J, Koziol JA. Filgrastim for cladribine-induced neutropenic fever in patients with hairy cell leukemia. Blood. 1999; 93 (8): 2471-2477.

  • Juliusson G, Lenkei R, Tjoennfjord G, Heldal D, Liliemark J. Neutropenic fever following cladribine therapy for symptomatic hairy-cell leukemia: predictive factors and effects of granulocytemacrophage colony-stimulating factor. Ann. Oncol. 1995; 6 (4): 371-375.

  • Shanafelt TD, Lin T, Geyer SM. Pentostatin, cyclophosphamide, and rituximab regimen in older patients with chronic lymphocytic leukemia. Cancer. 2007; 109 (11): 2291-2298.

  • Doxorubi Lyseng-Williamson KA, Fenton C. Docetaxel: a review of its use in metastatic breast cancer. Drugs. 2005; 65(17): 2513-2531.

  • Clarke SJ, Rivory LP. Clinical pharmacokinetics of docetaxel. Clin. Pharmacokinet. 1999; 36 (2): 99-114.

  • Anonymous. Oncology Tools: Approved Claims for microtubule inhibitors. US Food and Drug Administration. At web.archive.org 17 Sep. 2006. Last modified 22 Jun 1998.

  • Anonymous. Taxotere Docetaxel concentrates for infusion. Medsafe. http://www.medsafe.govt.nz/profs/Datasheet/ t/taxotereinf.htm 25 Sep 2006. Last modified 6 Feb 2006.

  • Anonymous. Taxotere.com for Healthcare Professionals: Efficacy and Safety. Sanofi-aventis U.S. LLC. http://www.taxotere.com/professional/about/efficacy_safety.do 24 Sep 2006. Last modifiedJul 2005.

  • Rang HP, Dale MM, Ritter JM, Moore PK. Pharmacology. 5th ed. London: Churchill Livingstone. 2003. pp. 694-698.

  • Doxorubicin (Systemic). Mayo Clinic. Last updated on: June 15, 1999. Retrieved on April 19, 2007.

  • Richard B, Annette B. 25 Most Asked Questions. Fighting Cancer. R. A. Bloch Cancer Foundation. http://www.blochcancer.org/fighting/chap13.html. Retrieved 2007-06-28.

  • Groopman J. How Doctors Think. Boston, houghton Mifflin Company. New York. 2007.

  • Appel IM, van Kessel-Bakvis C, Stigter R, Pieters R. Influence of two different regimens of concomitant treatment with asparaginase and dexamethasone on hemostasis in childhood acute lymphoblastic leukemia. Leukemia. 2007; 21: 2377.

  • Johnston A, Gudjonsson JE, Sigmundsdottir H, Ludviksson BR, Valdimarsson H. The anti-inflammatory action of methotrexate is not mediated by lymphocyte apoptosis, but by the suppression of activation and adhesion molecules. Clin Immunol. 2005; 114: 154-163.

  • Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, Martin Mola E, Pavelka K, Sany J, Settas L, Wajdula J, Pedersen R, Fatenejad S, Sanda M. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet. 2004; 363 (9410): 675-681.

  • British National Formulary. 39 Medline plus entry for Paclitaxel. Medline. Last revised April 1, 2003.

  • Saville M, Lietzau J, Pluda J, Feuerstein I, Odom J, Wilson W, Humphrey R, Feigal E, Steinberg S, Broder S. Treatment of HIVassociated Kaposi's sarcoma with paclitaxel. Lancet. 1995; 346 (8966): 26-28.

  • Sauter C, Lamanna N, Weiss MA. Pentostatin in chronic lymphocytic leukemia. Expert Opin Drug Metab Toxicol. 2008; 4 (9): 1217-1222.

  • Maloney DG, Grillo-Lopez AJ, White CA. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood. 1997; 90 (6): 2188- 2195.

  • Steiner AZ, Terplan M, Paulson RJ. Comparison of tamoxifen and clomiphene citrate for ovulation induction: a meta-analysis. Hum. Reprod. 2005; 20 (6): 1511-1515.

  • Van Bommel EF, Hendriksz TR, Huiskes AW, Zeegers AG. Brief communication: tamoxifen therapy for nonmalignant retroperitoneal fibrosis. Ann. Intern. Med. 2006; 144 (2): 101-106.

  • Boccardo F, Rubagotti A, Battaglia M, Di Tonno P, Selvaggi FP, Conti G, Comeri G, Bertaccini A, Martorana G, Galassi P, Zattoni F, Macchiarella A, Siragusa A, Muscas G, Durand F, Potenzoni D, Manganelli A, Ferraris V, Montefiore F. Evaluation of tamoxifen and anastrozole in the prevention of gynecomastia and breast pain induced by bicalutamide monotherapy of prostate cancer. J Clin Oncol. 2005; 23 (4): 808-815.

  • Gynecomastia-Gyno.com: Realistic Treatment Options. 2008.

  • Baker JS, Graham MR, Davies B. Steroid and prescription medicine abuse in the health and fitness community: A regional study. Eur. J. Intern. Med. 2006; 17 (7): 479-484.

  • Krum SA, Miranda-Carboni GA, Hauschka PV, Carroll JS, Lane TF, Freedman LP, Brown M. Estrogen protects bone by inducing Fas ligand in osteoblasts to regulate osteoclast survival. Embo J. 2008; 27 (3): 535-545.

  • Mincey BA, Moraghan TJ, Perez EA. Prevention and treatment of osteoporosis in women with breast cancer. Mayo Clin Proc. 2000; 75 (8): 821-829.

  • Vehmanen L, Elomaa I, Blomqvist C, Saarto T. Tamoxifen treatment after adjuvant chemotherapy has opposite effects on bone mineral density in premenopausal patients depending on menstrual status. J Clin Oncol. 2006. 24(4): 675-680.

  • Graf WD, Chance PF, Lensch MW, Eng LJ, Lipe HP, Bird TD. Severe vincristine neuropathy in Charcot-Marie-Tooth disease type 1A. Cancer. 1996; 77 (7): 1356-1362.

  • Qweider M, Gilsbach JM, Rohde V. Inadvertent intrathecal vincristine administration: a neurosurgical emergency. Case report. J Neurosurg Spine. 2007; 6 (3): 280-283.

  • Marty M, Fumoleau P, Adenis A, Rousseau Y, Merrouche Y, Robinet G, Senac I, Puozzo C. Oral vinorelbine pharmacokinetics and absolute bioavailability study in patients with solid tumors. Ann Oncol. 2001; 12 (11): 1643-1649.


Abstract Views: 460

PDF Views: 2




  • A New Profile of Therapeutic Potential and Toxicities of Antineoplastic Drugs

Abstract Views: 460  |  PDF Views: 2

Authors

R. D. Dubey
Institute of Pharmacy, RITEE, Chhatauna, Mandir Hasaud, Raipur, Chhattisgarh, India
A. R. Ahmad
Institute of Pharmacy, RITEE, Chhatauna, Mandir Hasaud, Raipur, Chhattisgarh, India
S. Paroha
Institute of Pharmacy, RITEE, Chhatauna, Mandir Hasaud, Raipur, Chhattisgarh, India
P. K. Sahu
Institute of Pharmacy, RITEE, Chhatauna, Mandir Hasaud, Raipur, Chhattisgarh, India
S. Verma
Institute of Pharmacy, RITEE, Chhatauna, Mandir Hasaud, Raipur, Chhattisgarh, India
S. J. Daharwal
Institute of Pharmacy, RITEE, Chhatauna, Mandir Hasaud, Raipur, Chhattisgarh, India
S. L. N. Prasad Reddy
Samskruti College of Pharmacy, Kondapur, Ghatkesar, RR Dist., Hyderabad, Andhra Pradesh, India
M. S. Qureshi
Anwarul Uloom College of Pharmacy, New Mallepally, Hyderabad, Andhra Pradesh, India

Abstract


Anticancer or antineoplastic drugs are used to treat malignancies. Drug therapy may be used alone or in combination with other treatments such as surgery or radiation therapy. The available anticancer drugs have distinct mechanisms of action which may vary in their effects on different types of normal and cancer cells. A single cure for cancer has proved elusive since there is not a single type of cancer but as many as 100 different types of cancer. In addition, there are very few demonstrable biochemical differences between cancerous cells and normal cells. For this reason the effectiveness of many anticancer drugs is limited by their toxicity to normal rapidly growing cells. A final problem is that cancerous cells which are initially suppressed by a specific drug may develop a resistance to that drug. For this reason cancer chemotherapy may consist of using several drugs in combination for varying lengths of time.

Keywords


Antineoplastic, Malignancies, Therapy, Toxicity.

References